Tetrabromocinnamic Acid (TBCA) and Related Compounds Represent a New Class of Specific Protein Kinase CK2 Inhibitors
- 15 December 2006
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 8 (1) , 129-139
Abstract
Abnormally high constitutive activity of protein kinase CK2, levels of which are elevated in a variety of tumours, is suspected to underlie its pathogenic potential. The most widely employed CK2 inhibitor is 4,5,6,7‐tetrabromobenzotriazole (TBB), which exhibits a comparable efficacy toward another kinase, DYRK1 a. Here we describe the development of a new class of CK2 inhibitors, conceptually derived from TBB, which have lost their potency toward DYRK1 a. In particular, tetrabromocinnamic acid (TBCA) inhibits CK2 five times more efficiently than TBB (IC50 values 0.11 and 0.56 μM, respectively), without having any comparable effect on DYRK1 a (IC50 24.5 μM) or on a panel of 28 protein kinases. The usefulness of TBCA for cellular studies has been validated by showing that it reduces the viability of Jurkat cells more efficiently than TBB through enhancement of apoptosis. Collectively taken, the reported data support the view that suitably derivatized tetrabromobenzene molecules may provide powerful reagents for dissecting the cellular functions of CK2 and counteracting its pathogenic potentials.Keywords
This publication has 51 references indexed in Scilit:
- The Amber biomolecular simulation programsJournal of Computational Chemistry, 2005
- Inhibition of Protein Kinase CK2 by Condensed Polyphenolic Derivatives. An in Vitro and in Vivo StudyBiochemistry, 2004
- The specificities of protein kinase inhibitors: an updateBiochemical Journal, 2003
- Inhibition of Protein Kinase CK2 by Anthraquinone-related CompoundsJournal of Biological Chemistry, 2003
- The Protein Data BankNucleic Acids Research, 2000
- Emodin, an Anthraquinone Derivative Isolated from the Rhizomes of Rheum palmatum, Selectively Inhibits the Activity of Casein Kinase II as a Competitive InhibitorPlanta Medica, 1999
- p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in miceOncogene, 1998
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94Journal of Computational Chemistry, 1996
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973